this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->

Chemical Component Summary

Identifiers(4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
FormulaC12 H20 N4 O7
Molecular Weight332.31 g/mol
Isomeric SMILESCC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)N=C(N)N

Chemical Details

Formal Charge0
Atom Count43
Chiral Atom Count5
Chiral AtomsC4 C5 C6 C7 C8
Bond Count43
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00558 Stereoisomeric match
  • approved
  • investigational
DescriptionA guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]
  • (2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
  • 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
  • 4-Guanidino-neu5ac2en
  • 5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
  • 5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
Brand NamesRelenza
Affected Organism
  • Influenza A virus
  • Influenza B virus
IndicationFor the prevention and treatment of influenza A and B.
PharmacologyZanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.
Mechanism of actionThe proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
Route of administration
  • Oral; Respiratory (inhalation)
  • Respiratory (inhalation)
  • Acids, Acyclic
  • Amidines
  • Amino Sugars
  • Anti-Infective Agents
  • Antiinfectives for Systemic Use
CAS number139110-80-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682